Coastlands Capital LP has disclosed a significant investment in Sutro Biopharma, Inc. The firm reported holding 5.14% of Sutro's common stock, amounting to 852,669 shares. This move highlights Coastlands' growing interest in the biological products sector.

The filing, submitted on November 9, 2026, indicates that the investment is part of Coastlands Capital's strategy to engage more deeply in the life sciences market. Sutro Biopharma focuses on developing innovative therapeutics, which could attract further investments from firms looking to capitalize on advancements in biotechnology.

Background

Coastlands Capital LP is a Delaware limited partnership based in San Francisco, California. The firm specializes in investment management and has been active in filing various forms with the SEC, including recent filings on November 6 and November 3, 2026. Sutro Biopharma, Inc., the subject of this investment, operates in the biological products sector, specifically focusing on innovative therapies.

What the Filing Says

The filing states, "Consists of 852,669 shares of Common Stock held directly by Coastlands Capital Partners LP." This stake represents a significant share of Sutro Biopharma's total outstanding shares, which were reported as 16,581,171 as of August 7, 2026.

Impact

This disclosure may impact various stakeholders, including Sutro Biopharma's management, other investors, and competitors in the biological products market. The increased investment from Coastlands Capital could signal confidence in Sutro's future prospects, potentially influencing other investors' decisions.

What's Next

The filing does not say what happens next regarding this investment or any potential actions by Coastlands Capital or Sutro Biopharma.